Table 1 The effects of signaling path-ways inhibitors on MMe
From: DNA repair and damage pathways in mesothelioma development and therapy
Signaling | Inhibitor | Effect | Refs. |
|---|---|---|---|
HH signaling | HhAntag (SMO antagonist) | 35% ↓tumor volume and 32% ↓YAP protein and ↓SOX2 and survivin, ↓tumor growth | [14] |
Vismodegib | Gli1↓, Hhip↓, Ptch1↓, ↓tumor growth and ↓proliferation | [17] | |
GDC-0449 | ↓proliferation | [19] | |
GANT61 | ↓proliferation | [19] | |
Cyclopamine | GLI1↓, PTCH1↓, SHH↓, SMO↓, and ↓proliferation | [20] | |
PI3K/mTOR signaling | BEZ235 | ↓cell viability and ↓proliferation | [27] |
Apitolisib with Platinum-pemetrexed chemotherapy | ↓tumor volume, ↓symptoms, ↓CA-125 | [28] | |
BEZ235 and BYL719 with palbociclib | ↓proliferation and↑ cellular senescence | [32] | |
NVP-BEZ235 and GDC-0980 with Chloroquine | ↓autophagy and ↓ cell death resistance | [33] | |
MAPK/ERK signaling and AKT/mTOR signaling | Pirfenidone alone or with cisplatin | ↓proliferation | [42] |